Plasma Uracil as a DPD Phenotyping Test: Pre-Analytical Handling Matters!

Clinical Pharmacology & TherapeuticsVolume 113, Issue 3 p. 471-472 Letter to the Editor Plasma Uracil as a DPD Phenotyping Test: Pre-Analytical Handling Matters! Fabienne Thomas, Corresponding Author Fabienne Thomas [email protected] orcid.org/0000-0001-9886-412X Centre de Recherches en Cancérologie, Inserm, CNRS, Université Toulouse III-Paul Sabatier and IUCT-Oncopole, Toulouse, FranceCorrespondence: Fabienne Thomas ([email protected])Search for more papers by this authorManon Launay, Manon Launay orcid.org/0000-0003-3113-7301 Plateau de Biologie, CHU Saint Etienne, Saint Etienne, FranceSearch for more papers by this authorJérôme Guitton, Jérôme Guitton Laboratoire de Pharmacologie Toxicologie, CHU de Lyon, Lyon, FranceSearch for more papers by this authorMarie-Anne Loriot, Marie-Anne Loriot Department of Clinical Chemistry, Hôpital Européen Georges Pompidou, Assistance Publique-Hôpitaux de Paris, Paris, France INSERM UMRS1138, Centre de Recherche des Cordeliers, Université de Paris, Paris, FranceSearch for more papers by this authorJean-Christophe Boyer, Jean-Christophe Boyer Biochemistry Laboratory, Carrémeau University Hospital, Nîmes, FranceSearch for more papers by this authorVincent Haufroid, Vincent Haufroid orcid.org/0000-0001-5040-9806 Department of Clinical Chemistry, Cliniques Universitaires Saint-Luc and Louvain Centre for Toxicology and Applied Pharmacology (LTAP), Institut de Recherche Expérimentale et Clinique, UCLouvain, Brussels, BelgiumSearch for more papers by this authorMarie-Christine Etienne-Grimaldi, Marie-Christine Etienne-Grimaldi Oncopharmacology Laboratory, Centre Antoine Lacassagne, Nice, FranceSearch for more papers by this authorBernard Royer, Bernard Royer Laboratoire de Pharmacologie Clinique et Toxicologie, CHU Besançon, Besançon, France INSERM, EFS BFC, UMR1098, Interactions Hôte-Greffon-Tumeur/Ingénierie Cellulaire et Génique, University of Bourgogne Franche-Comté, Besançon, FranceSearch for more papers by this authorthe GPCO-UNICANCER Group, the GPCO-UNICANCER GroupSearch for more papers by this author Fabienne Thomas, Corresponding Author Fabienne Thomas [email protected] orcid.org/0000-0001-9886-412X Centre de Recherches en Cancérologie, Inserm, CNRS, Université Toulouse III-Paul Sabatier and IUCT-Oncopole, Toulouse, FranceCorrespondence: Fabienne Thomas ([email protected])Search for more papers by this authorManon Launay, Manon Launay orcid.org/0000-0003-3113-7301 Plateau de Biologie, CHU Saint Etienne, Saint Etienne, FranceSearch for more papers by this authorJérôme Guitton, Jérôme Guitton Laboratoire de Pharmacologie Toxicologie, CHU de Lyon, Lyon, FranceSearch for more papers by this authorMarie-Anne Loriot, Marie-Anne Loriot Department of Clinical Chemistry, Hôpital Européen Georges Pompidou, Assistance Publique-Hôpitaux de Paris, Paris, France INSERM UMRS1138, Centre de Recherche des Cordeliers, Université de Paris, Paris, FranceSearch for more papers by this authorJean-Christophe Boyer, Jean-Christophe Boyer Biochemistry Laboratory, Carrémeau University Hospital, Nîmes, FranceSearch for more papers by this authorVincent Haufroid, Vincent Haufroid orcid.org/0000-0001-5040-9806 Department of Clinical Chemistry, Cliniques Universitaires Saint-Luc and Louvain Centre for Toxicology and Applied Pharmacology (LTAP), Institut de Recherche Expérimentale et Clinique, UCLouvain, Brussels, BelgiumSearch for more papers by this authorMarie-Christine Etienne-Grimaldi, Marie-Christine Etienne-Grimaldi Oncopharmacology Laboratory, Centre Antoine Lacassagne, Nice, FranceSearch for more papers by this authorBernard Royer, Bernard Royer Laboratoire de Pharmacologie Clinique et Toxicologie, CHU Besançon, Besançon, France INSERM, EFS BFC, UMR1098, Interactions Hôte-Greffon-Tumeur/Ingénierie Cellulaire et Génique, University of Bourgogne Franche-Comté, Besançon, FranceSearch for more papers by this authorthe GPCO-UNICANCER Group, the GPCO-UNICANCER GroupSearch for more papers by this author First published: 22 November 2022 https://doi.org/10.1002/cpt.2772 Linked articles: “Dihydropyrimidine Dehydrogenase Phenotyping Using Pretreatment Uracil: A Note of Caution Based on a Large Prospective Clinical Study” by de With M, et al. Clin Pharmacol Ther. 112, 62–68 (2022). doi: 10.1002/cpt.2608; and Response to “Plasma Uracil as a DPD Phenotyping Test: Pre-analytical Handling Matters” by de With, M. et al. Clin. Pharmacol. Ther. 113, 473–475 (2023). https://doi.org/10.1002/cpt.2775 Read the full textAboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL No abstract is available for this article. Volume113, Issue3March 2023Pages 471-472 RelatedInformation